文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

趋化因子在协调针对胰腺导管腺癌的免疫反应中的作用

The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.

作者信息

Lekan Alexander A, Weiner Louis M

机构信息

Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA.

出版信息

Cancers (Basel). 2024 Jan 28;16(3):559. doi: 10.3390/cancers16030559.


DOI:10.3390/cancers16030559
PMID:38339310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10854906/
Abstract

Chemokines are small molecules that function as chemotactic factors which regulate the migration, infiltration, and accumulation of immune cells. Here, we comprehensively assess the structural and functional role of chemokines, examine the effects of chemokines that are present in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME), specifically those produced by cancer cells and stromal components, and evaluate their impact on immune cell trafficking, both in promoting and suppressing anti-tumor responses. We further explore the impact of chemokines on patient outcomes in PDAC and their role in the context of immunotherapy treatments, and review clinical trials that have targeted chemokine receptors and ligands in the treatment of PDAC. Lastly, we highlight potential strategies that can be utilized to harness chemokines in order to increase cytotoxic immune cell infiltration and the anti-tumor effects of immunotherapy.

摘要

趋化因子是作为趋化因子发挥作用的小分子,可调节免疫细胞的迁移、浸润和聚集。在此,我们全面评估趋化因子的结构和功能作用,研究胰腺导管腺癌(PDAC)肿瘤微环境(TME)中存在的趋化因子的作用,特别是癌细胞和基质成分产生的趋化因子,并评估它们对免疫细胞转运的影响,包括促进和抑制抗肿瘤反应。我们进一步探讨趋化因子对PDAC患者预后的影响及其在免疫治疗中的作用,并回顾针对趋化因子受体和配体治疗PDAC的临床试验。最后,我们强调可用于利用趋化因子以增加细胞毒性免疫细胞浸润和免疫治疗抗肿瘤效果的潜在策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/7b170d7f6ce0/cancers-16-00559-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/94c085d23ae0/cancers-16-00559-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/cabdfdb1852c/cancers-16-00559-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/7b170d7f6ce0/cancers-16-00559-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/94c085d23ae0/cancers-16-00559-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/cabdfdb1852c/cancers-16-00559-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd32/10854906/7b170d7f6ce0/cancers-16-00559-g003.jpg

相似文献

[1]
The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.

Cancers (Basel). 2024-1-28

[2]
M1 Macrophage-Derived TNF-α Promotes Pancreatic Cancer Ferroptosis Via p38 MAPK-ACSL4 Pathway.

Curr Mol Med. 2025-7-10

[3]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[4]
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.

Sci Transl Med. 2024-10-23

[5]
TYROBP overexpression alters macrophage phenotype and enhances pancreatic cancer stemness through STAT3 and PKM2 signaling.

Cell Signal. 2025-6-17

[6]
Activation of the integrated stress response (ISR) pathways in response to Ref-1 inhibition in human pancreatic cancer and its tumor microenvironment.

Front Med (Lausanne). 2023-4-27

[7]
Drug resistant pancreatic cancer cells exhibit altered biophysical interactions with stromal fibroblasts in imaging studies of 3D co-culture models.

Sci Rep. 2024-9-5

[8]
Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma.

bioRxiv. 2025-5-24

[9]
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity.

J Immunother Cancer. 2023-11

[10]
Natural killer cells associate with epithelial cells in the pancreatic ductal adenocarcinoma tumor microenvironment.

bioRxiv. 2024-5-28

引用本文的文献

[1]
Cancer-Associated Fibroblasts: Immunosuppressive Crosstalk with Tumor-Infiltrating Immune Cells and Implications for Therapeutic Resistance.

Cancers (Basel). 2025-7-28

[2]
α-Asarone attenuates tumor-associated macrophages-induced gemcitabine resistance in pancreatic carcinoma via the transforming growth factor-beta 1/growth factor independent 1 axis.

Anticancer Drugs. 2025-9-1

[3]
Periprostatic Adipose Tissue as a Contributor to Prostate Cancer Pathogenesis: A Narrative Review.

Cancers (Basel). 2025-1-23

[4]
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

J Hematol Oncol. 2025-1-13

[5]
Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors.

Cancer Sci. 2024-11

[6]
Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions.

Cancers (Basel). 2024-7-2

本文引用的文献

[1]
Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.

Front Immunol. 2023

[2]
Proteasome-dependent senescent tumor cells mediate immunosuppression through CCL20 secretion and M2 polarization in pancreatic ductal adenocarcinoma.

Front Immunol. 2023

[3]
CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma.

Am J Transl Res. 2023-4-15

[4]
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.

Nat Cancer. 2023-6

[5]
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.

JCO Precis Oncol. 2023-4

[6]
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.

Cancer Discov. 2023-6-2

[7]
CAFs secrete CXCL12 to accelerate the progression and cisplatin resistance of colorectal cancer through promoting M2 polarization of macrophages.

Med Oncol. 2023-2-3

[8]
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.

Front Immunol. 2022

[9]
Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.

Adv Sci (Weinh). 2023-1

[10]
CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype.

Oncogene. 2023-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索